This observation has recently been documented in metastatic melanoma patients in the context of immune checkpoint inhibition as monotherapy (PD-1/PD-L1 or CTLA-4) and targeted therapy in a pooled meta-analysis, but not of chemotherapy [19]. The gene discussed is CD274; the disease is metastatic melanoma.